SLC2A1 and cancer: Several studies have pointed out the potential of the SLC transporter family in drug discovery (Lin et al., 2015; Rives et al., 2017; Scalise et al., 2019; Schumann et al., 2020), and SLC2A1 has been included as a key gene for diagnostic or prognostic cancer signature prediction in several cancers (Mo et al., 2020; Chen et al., 2021a; Qin et al., 2021; Chen et al., 2022).